

Please type a plus sign (+) inside this box → [+]

PTO/SB08A/B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	
Confirmation Number	
Filing Date	January 16, 2004
First Named Inventor	Stanislaw (NMN) Pikul
Group Art Unit	1626
Examiner Name	Robert W. Ramsuer
Attorney Docket Number	7989RD

SHEET 1 of 3

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
DN <					

49	US- 6,028,110	02/22/2000	Miller, et al.	
50	US- 6,124,332	09/26/2000	Miller, et al.	
51	US- 5,962,529	10/05/1999	Miller, et al.	
52	US- 6,022,898	02/08/2000	Miller, et al.	
53	US- 6,066,662	05/23/2000	Broadhurst, et al.	
54	US- 6,124,329	09/26/2000	Miller, et al.	
55	US- 6,124,333	09/26/2000	Miller, et al.	
56	US- 5,763,621	06/09/1998	Beckett, et al.	
57	US- 6,166,082	12/26/2000	Kluender, et al.	
58	US- 5,886,022	03/23/1999	Kluender, et al.	
59	US- 6,225,311 B1	05/01/2001	Levin, et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	FOREIGN PATENT DOCUMENT			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T*
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
60	GB 2 268 934 A				01/26/1994	Dickens, et al.		
61	EP 0 575 844 B1				01/21/1998	Broadhurst, et al.		
62	EP 0 895 988 A1				02/10/1999	Robinson		
63	EP 0 606 046 A1				07/13/1994	MacPherson, et al.		
64	EP 0 950 656 A1				10/20/1999	Watanabe, et al.		
65	EP 0 979 816 A1				02/16/2000	Hanessian, et al.		
66	EP 0 877 018 A1				11/11/1998	Thorwart, et al.		
67	WO 92/17460				10/15/1992	Markwell, et al.		
68	WO 93/14112				07/22/1993	Caldwell, et al.		
69	WO 94/25435				11/10/1994	Morphy, et al.		
70	WO 95/12603				05/11/1995	Castelano, et al.		
71	WO 95/29892				11/09/1995	DeCicco, et al.		
72	WO 95/33731				12/14/1995	Broadhurst, et al.		
73	WO 96/00214				01/04/1996	MacPherson, et al.		
74	WO 98/39329				09/11/1998	Heintz, et al.		
75	WO 00/51993				09/08/2000	Cheng, et al.		
76	WO 00/51993 A3				09/08/2000	Cheng, et al.		
77	WO 00/73294 A2				12/07/2000	Reiter		
78	WO 00/73295 A1				12/07/2000	Reiter		
79	WO 99/42443				08/26/1999	Kukkola, et al.		
80	WO 99/06340				02/11/1999	Almstead, et al.		
81	WO 99/52889				10/21/1999	Reiter		
82	JP 07-304770				11/21/1995	Masahiro, et al.		Y
83	JP 08-053403				02/27/1996	Ichiro, et al.		Y
84	WO 97/22587				06/26/1997	Parker		
85	WO 98/33768				08/06/1998	Robinson, et al.		
86	WO 99/18079				04/15/1999	Purchase, et al.		

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T*
BN	87	J. NEMUNAITIS, et al., "Combined Analysis of Studies of the Effects of the Matrix Metalloproteinase Inhibitor Marimastat on Serum Tumor Markers in Advanced Cancer: Selection of a Biologically Active and Tolerable Dose for Longer-term Studies", <u>Clinical Cancer Research</u> , Vol.4, pp. 1101-1109 (1998).	
	88	A. E. YU, et al., "Matrix Metalloproteinases – Novel Targets for Directed Cancer Therapy", <u>Drugs and Aging</u> , Vol. 11, No. 3, pp. 229 – 244 (1997).	
	89	J. BIRD, et al., "Synthesis of Novel N-Phosphonoalkyl Dipeptide Inhibitors of Human Collagenase", <u>Journal of Medicinal Chemistry</u> , Vol. 37, No. 1, pp. 158 – 169 (1994).	
	90	K. GJBELS, et al., "Reversal of Experimental Autoimmune Encephalomyelitis with a Hydroxamate Inhibitor of Matrix Metalloproteases", <u>J. Clin. Invest.</u> , Vol. 94, pp. 2177 – 2182 (1994).	
	91	B. HENDERSON, et al., "Design of Inhibitors of Articular Cartilage Destruction", <u>Drugs of the Future</u> , Vol. 15, No. 5, pp. 495 – 508 (1990).	
	92	A. F. CHAMBERS, et al., "Changing Views of the Role of Matrix Metalloproteinases in Metastasis", <u>Journal of the National Cancer Institute</u> , Vol. 89, No. 17, pp. 1260 – 1270 (1997).	
	93	R. REICH, et al., " Effects of Inhibitors of Plasminogen Activator, Serine Proteinases, and Collagenase IV on the Invasion of Basement Membranes by Metastatic Cells" <u>Cancer Research</u> , Vol. 48, pp. 3307 – 3312 (1988).	
	94	T. G. WOLFSBERG, et al., "ADAM, a Novel Family of Membrane Proteins Containing A Disintegrin And Metalloprotease Domain: Multipotential Functions in Cell-Cell and Cell-Matrix Interactions", <u>The Journal of Cell Biology</u> , Vol. 131, No. 2, pp. 275 – 278 (1995).	
	95	H. S. RASMUSSEN, et al., "Matrix Metalloproteinase Inhibition as a Novel Anticancer Strategy: A Review with Special Focus on Batimastat and Marimastat", <u>Pharmacol. Ther.</u> , Vol. 75, No. 1, pp. 69 – 75 (1997).	

<i>MS</i>	96	D. E. MULLINS, et al., "The Role of Proteinases in Cellular Invasiveness", <u>Biochimica et Biophysica Acta</u> , Vol. 695, pp. 177 – 214 (1983).	
<i>MS</i>	97	S. R. BRAMHALL, "The Matrix Metalloproteinases and Their Inhibitors in Pancreatic Cancer", <u>International Journal of Pancreatology</u> , Vol. 21, No. 1, pp. 1 – 12 (1997).	
<i>MS</i>	98	J. R. MORPHY, et al. "Matrix Metalloproteinase Inhibitors: Current Status", <u>Current Medicinal Chemistry</u> , Vol. 2, pp. 743 – 762 (1995).	
EXAMINER <i>D. Lambhur</i>		DATE CONSIDERED <i>3/10/05</i>	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.